Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.340
0.00 (0.00%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Calidi Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.07 | 5.6 | 9.59 | 1.95 | 0.37 | 2.14 |
Cash & Short-Term Investments | 4.07 | 5.6 | 9.59 | 1.95 | 0.37 | 2.14 |
Cash Growth | -22.88% | -41.61% | 392.10% | 423.93% | -82.59% | 408.81% |
Other Receivables | - | - | - | 1.36 | - | - |
Receivables | - | - | - | 1.36 | - | - |
Prepaid Expenses | 1.36 | 0.42 | 0.39 | 0.77 | 0.31 | 0.5 |
Restricted Cash | - | - | - | - | 0.1 | 0.1 |
Other Current Assets | - | 0.23 | 0.25 | 0.23 | - | - |
Total Current Assets | 5.43 | 6.26 | 10.23 | 4.3 | 0.79 | 2.74 |
Property, Plant & Equipment | 1.77 | 2.46 | 3.8 | 5.34 | 1.09 | 0.59 |
Other Long-Term Assets | 0.01 | 0.14 | 0.15 | 0.37 | 0.73 | 0.07 |
Total Assets | 7.2 | 8.86 | 14.18 | 10.02 | 2.6 | 3.39 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.93 | 0.61 | 2.07 | 2.88 | 2.27 | 0.62 |
Accrued Expenses | 1.13 | 1.81 | 2.98 | 5.43 | 5.35 | 3.51 |
Short-Term Debt | - | - | 0.47 | 0.53 | 3.46 | 5 |
Current Portion of Long-Term Debt | - | - | 2.7 | 0.28 | 1.96 | - |
Current Portion of Leases | 1.18 | 1.52 | 1.27 | 1.12 | 0.12 | 0.14 |
Other Current Liabilities | - | - | - | - | 29.83 | 16.69 |
Total Current Liabilities | 3.24 | 3.94 | 9.5 | 10.23 | 42.99 | 25.96 |
Long-Term Debt | 0.6 | 0.6 | 0.6 | 2.06 | - | - |
Long-Term Leases | 0.17 | 0.45 | 1.99 | 3.25 | 0.45 | 0.04 |
Other Long-Term Liabilities | 0.07 | 0.12 | 0.13 | 2.71 | - | - |
Total Liabilities | 4.07 | 5.1 | 12.21 | 18.25 | 43.44 | 26 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 3.13 | 0 | - | 0 | 0 | 0 |
Additional Paid-In Capital | - | 145.39 | 123.28 | 91.38 | 19.93 | 13.32 |
Retained Earnings | - | -141.62 | -121.72 | -99.57 | -70.36 | -44.93 |
Comprehensive Income & Other | - | -0.01 | -0.03 | -0.05 | -0.01 | -0 |
Total Common Equity | 3.13 | 3.76 | 1.53 | -8.24 | -50.44 | -31.61 |
Minority Interest | - | - | 0.43 | - | - | - |
Shareholders' Equity | 3.13 | 3.76 | 1.97 | -8.24 | -40.84 | -22.61 |
Total Liabilities & Equity | 7.2 | 8.86 | 14.18 | 10.02 | 2.6 | 3.39 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.94 | 2.56 | 7.04 | 7.24 | 5.99 | 5.18 |
Net Cash (Debt) | 2.13 | 3.04 | 2.56 | -5.29 | -5.62 | -3.04 |
Net Cash Growth | 67.90% | 18.83% | - | - | - | - |
Net Cash Per Share | 3.03 | 11.29 | 61.29 | - | - | -295.96 |
Filing Date Shares Outstanding | 1.42 | 0.69 | 0.16 | 0.02 | 20.62 | 19.93 |
Total Common Shares Outstanding | 1.42 | 0.46 | 0.12 | 0.02 | 20.62 | 19.93 |
Working Capital | 2.19 | 2.32 | 0.73 | -5.93 | -42.2 | -23.22 |
Book Value Per Share | 2.21 | 8.16 | 13.06 | -445.14 | -2.45 | -1.59 |
Tangible Book Value | 3.13 | 3.76 | 1.53 | -8.24 | -50.44 | -31.61 |
Tangible Book Value Per Share | 2.21 | 8.16 | 13.06 | -445.14 | -2.45 | -1.59 |
Machinery | - | 1.8 | 1.64 | 1.66 | 1.1 | 0.68 |